bullish
Samsung Biologics (207940 KS): Record High Revenue in 2024; Accelerated Growth Expected in 2025
386 Views22 Jan 2025 10:38
SUMMARY
- Samsung Biologics (207940 KS) reported 2024 revenue of KRW4.55T, up 23% YoY, ahead of guidance of 15–20%. Growth was driven by increased contribution from Plant 4 and milestone payment.
- Ramp-Up at Plant 4 is expected to drive further revenue growth, while Plant 5, scheduled to begin operations in April 2025, will expand total production capacity to 784,000 liters.
- Samsung Biologics is well positioned to be resilient to the industry challenges. The company has guided for 20–25% YoY revenue growth to KRW5456–5684B in 2025.
Related Insights
More »- Samsung Biologics (207940 KS): 1Q25 Operating and Net Profits Doubled; 2025 Guidance Maintained
- 4 Key Movers in TIGER Top 10 in June Reshuffle
- Samsung Biologics (207940 KS): Record High Revenue in 2024; Accelerated Growth Expected in 2025
- Samsung Biologics (207940 KS): 3Q Result Beat Expectation; Guidance Raise Amid Increasing Order Book
- Trading Plays on Samsung C&T’s Holding Company Shift and Biologics Share Sell-Off
Trending Collections
More »Trending Insights
More »- Quiddity Leaderboard CSI 300/500 Jun25: Momentum Turning Positive for This Major Rebal Trade
- Crude Awakening: Shell’s Possible Bid to Refine BP’s Future
- Smartpay (SPY NZ/SMP AU): Three Is No Crowd as a Third Bid Lands at NZ$1.20
- CATL H Share Listing: AH Discount Views
- CapitaLand Investment Ltd - Slow start
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Samsung Biologics (207940 KS): 1Q25 Operating and Net Profits Doubled; 2025 Guidance Maintained24 Apr 2025
- Samsung Biologics (207940 KS): Record High Revenue in 2024; Accelerated Growth Expected in 202522 Jan 2025
- Samsung Biologics (207940 KS): 3Q Result Beat Expectation; Guidance Raise Amid Increasing Order Book23 Oct 2024
- Samsung Biologics (207940 KS): Strong 2Q24 Result; Annual Revenue to Surpass KRW4 Trillion25 Jul 2024
- Samsung Biologics (207940 KS): Gaining Momentum on New Approval and Contract Wins; Hold Shares02 Jul 2024
x